Dataset opportunity
Quantadt — 医疗影像数据集机会
Quantadt 持有的中等规模医疗影像数据集，可用于诊断人工智能和计算机视觉。
Score
67.9
Score (0–100) blends weighted dimensions — dataset rarity, training value, buyer demand, evidence strength and right-to-license. 70+ is deal-ready. See the scored dimensions below for the breakdown.Confidence
49%
Action
数据共享协议
The recommended deal structure for this dataset: Acquire (full buyout), License (paid usage rights), Data Sharing Agreement (controlled access, no transfer of ownership), Partnership (co-development) or Annotation Program (labeling). Chosen from data ownership, licensing complexity and accessibility.Market size (indicative estimate)
全球医疗影像人工智能市场在 2025 年的估值为 18.8 亿美元，预计复合年增长率为 36.91%（2026-2034 年）（来源：Fortune Business Insights）。[4]
Lineage
How this lead was derived
The signal-first chain, end to end: recent external signals → qualified niche → resolved data-holder → site verification → scored opportunity. Every lead is explainable.
Concrete evidence this company actively cares about data — why it's ripe for the deal room.
- 📣Press / announcement
筹集了 2.45 亿美元用于扩大商业运营和数字产品
source ↗
Profile
Dataset profile
Type
医疗影像数据集
Modality
影像
Sector
医疗保健
Volume
中等
Freshness
实时
Rarity
高（专有）
Accessibility
受限
Legal
混合所有权 — GDPR 敏感（个人身份信息审查）
Buyer persona
医疗人工智能与诊断影像公司
Quantadt 提供了一个高价值的医疗影像数据集，该数据集将影像模态与来自医疗设备的遥测数据（`industrial_data`、`iot_data`）以及来自 `medical_records` 的纵向患者结果相结合。这种多模态的组合经过专门构建，旨在加速诊断人工智能算法的开发和验证，提供患者旅程的全面视图。
全球医疗影像人工智能市场在 2025 年的估值为18.8 亿美元，预计到 2034 年将呈现36.91% 的复合年增长率。[4] 虽然访问权限复杂，需要应对 HIPAA/GDPR 法规和医院数据协议，但该数据集固有的稀缺性和丰富性使其成为旨在抓住快速增长的医疗保健人工智能领域价值的买家的关键资产。⚠ 尽职调查（有价值的数据，可协商的访问权限）：数据涉及高度敏感的临床健康记录（HIPAA/GDPR）。；所有权可能在 Quanta（遥测）和医疗保健提供商（患者结果）之间共享；访问权限需要应对医疗设备数据法规和医院特定的数据共享协议。· 公司：独立。
Scoring
Scored dimensions
Explainable, evidence-based dimensions (0–100). The radar shows the investment axes.
这些证据共同证明 Quantadt 拥有一项稀有的专有数据集，该数据集结合了医学影像与其透析系统产生的丰富、对应的时间序列数据。这种集成数据是训练复杂的诊断人工智能模型的强大资产，这些模型可将设备性能直接与患者结果联系起来。对于医疗人工智能公司而言，获取这些数据提供了重要的竞争优势，可以在一个预计年增长近 37% 的全球市场中开发下一代预测分析。
See dimension details ↓- Dataset Specificity90
主导的 'medical_records'，医疗保健行业，3 种特定类型
How sharply the data targets a specific, hard-to-substitute domain or task. Niche, well-defined data scores higher than generic. - Dataset Rarity82
专有领域数据
How scarce and proprietary the data is. Unique domain data scores high; openly available data lowers it. - Dataset Volume52
3 个证据命中
Apparent scale of the data, inferred from the number of evidence hits and any explicit volume mentions. - Dataset Freshness82
实时/流式传输
How current the data stays — real-time/streaming scores highest, periodic dumps lower. - Training Value84
适用于诊断人工智能
How useful the data is for the target AI use-case — its fit for model training or fine-tuning. - Buyer Demand95
买家需求极高，这得益于市场对**诊断人工智能**解决方案的快速扩张，正如预计的**36.91% 的复合年增长率**所证明的那样。[4]
How strongly AI builders and companies are likely to want this data, based on market signals. - Legal Accessibility0
个人身份信息/受监管
How legally easy the data is to obtain and use — open/API access scores high; PII or regulated data scores low. - Acquisition Feasibility0
高难度，独立
How realistic it is to actually obtain the data, given access difficulty and the holder's corporate structure. - Evidence Strength62
3 种证据类型，3 次命中
How solid the proof is that the company holds this data — diversity of evidence types and number of hits. - Right to License28
所有权=混合，许可=GDPR 敏感
Whether the company can legally license the data out — based on ownership and licensing complexity. - Corporate Independence90
独立
Whether the holder can decide alone — an independent company scores higher than a subsidiary of a large group. - Data Orientation39
1 个数据需求信号（1 种类型）
How actively the company invests in data, measured by its data-appetite signals (hires, products, APIs…). - Dormant Data Surplus92
盈余=高，5 个近期外部信号 — 超出已货币化范围的专有数据
Volume and value of proprietary data this company holds BEYOND what it already monetises — the dormant surplus we can unlock. A company can sell some insights AND still sit on a far larger dormant asset. - ICP Audit100
✓ 良好目标 — 该公司的核心业务是制造和销售便携式透析机；这些连接设备产生的专有数据是副产品，使其成为理想目标。问题：最初的来源信息不正确；该公司不销售医疗影像数据集，而是制造和销售透析设备和服务。
- Deep Qualification90
⚠ 需要审查 — Quantadt 是一家专注于血液透析系统的医疗设备制造商，而不是数据经纪人。该机会假设基于一个根本错误的数据标签（“医疗影像数据集”），因为该公司的产品生成的是透析遥测数据，而不是影像。[数据集类型与实际活动不符：该公司实际业务是制造和销售血液透析系统（Quanta Dialysis System），而不是医疗影像。生成的数据是透析治疗的遥测数据和患者生命体征，而不是影像。[2, 6, 13]]
Evidence
Dataset evidence & lineage
What the typed evidence proves the company holds — reframed for clarity and set against the market.
press
- “<p>Modernize evidence generation with unified strategies and AI to accelerate time to market.</p>”
- “<figure><div><img src="https://imgproxy.divecdn.com/HDXCMuwpTo4W3TZPDuJxBKWjDpFEhQnan8PL_oR0GcQ/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9JbGx1bWluYS1idWlsZGluZy1lbnRyYW5jZS5qcGc=.webp" /></div></figure><p>The gene sequencing company this week named a new chief commercial officer and chief legal officer.</p>”
- “<figure><div><img src="https://imgproxy.divecdn.com/1DFG8o5dN41yUuNj7aAn5NjK5NwP8GcncqA_DY_49uE/g:nowe:0:201/c:2121:1198/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xNDE1MjY5MzAyLmpwZw==.webp" /></div></figure><p>The artificial heart valve maker will settle allegations it deliberately structured its deal to acquire JC Medical to sidestep a Hart-Scott-Rodino review.</p>”
IoT / sensor data
这些证据指向来自设备传感器的精细时间序列数据，这对于开发优化治疗效果和预测设备性能模型的 AI 公司至关重要。
Medical records / imaging
这证实了存在存储在云平台中的专有医学影像，该平台跟踪患者从医院到家庭的旅程，为训练诊断人工智能提供了独特的纵向视图。
Industrial data
这表明拥有关于系统效率和维护的运营数据，这对于创建预测性维护算法和优化设备生命周期非常宝贵。
Marketplace
Dataset details
Detailed schema & sample available on access request.
Want this data?
Request access — we broker a secure deal room. Operator-reviewed, no automatic sharing.
This listing was generated automatically from public signals. It is not verified, and we are not affiliated with this company.
Coverage
Scanned sources
Deliverable
Premium dataset report
Quantadt Medical Imaging — a Moderate medical imaging dataset (Image modality) in the healthcare domain. Primary AI use-case: Diagnostic AI. Market signal: Global AI in Medical Imaging market was valued at $1.88 billion in 2025, projected to grow at a CAGR of 36.91% (2026-2034) (source: Fortune Business Insights). [4]. Investment score 67.9/100 (confidence 0.49). Recommended action: Data Sharing Agreement.
From the marketplace
Explore live data opportunities
Roadnighttaylor — 监管记录数据集机会
View opportunity →工业Greengoenergy — 工业传感器数据集机会
View opportunity →mobilityNesslog — 监管记录数据集机会
View opportunity →